Metsera, Inc. prices its IPO at $18 per share, raising approximately $275 million to fund obesity treatments.
Quiver AI Summary
Metsera, Inc., a clinical-stage biotechnology company specializing in obesity treatments through injectable and oral hormone analog peptides, announced the pricing of its initial public offering (IPO) of 15,277,778 shares at $18.00 each, aiming to raise approximately $275 million before expenses. The shares will trade on the Nasdaq under the ticker "MTSR" starting January 31, 2025, with the offering expected to close on February 3, 2025, pending customary conditions. The company has allowed underwriters a 30-day option to purchase an additional 2,291,666 shares. Major investment firms such as BofA Securities, Goldman Sachs, and others are acting as joint bookrunners for the offering, which is made under a registration statement filed with the SEC.
Potential Positives
- Metsera, Inc. successfully priced its initial public offering at $18.00 per share, indicating strong investor interest.
- The offering is expected to generate approximately $275.0 million in gross proceeds, providing significant capital for the company's growth and development efforts.
- Metsera's common stock will begin trading on the prestigious Nasdaq Global Select Market, enhancing its visibility and credibility in the investment community.
- The company has granted underwriters a 30-day option to purchase additional shares, potentially increasing the total capital raised from the offering.
Potential Negatives
- The company is heavily reliant on its initial public offering to raise substantial funds ($275 million), which indicates it may not have sufficient existing capital to support its operations or development initiatives.
- The offering is entirely comprised of shares offered by Metsera, which could signal that existing investors are not participating in the IPO, potentially raising concerns about their confidence in the company's future prospects.
- The necessity of a registration statement and formal prospectus process may highlight regulatory scrutiny and potential risks associated with investing in a clinical-stage biotechnology company.
FAQ
What is Metsera's initial public offering (IPO) date?
Metsera's IPO is expected to begin trading on the Nasdaq Global Select Market on January 31, 2025.
How many shares is Metsera offering in the IPO?
Metsera is offering 15,277,778 shares of its common stock in the IPO.
What is the price per share for Metsera's IPO?
The price per share for Metsera's initial public offering is $18.00.
What are the expected gross proceeds from the IPO?
The gross proceeds from Metsera's IPO are expected to be approximately $275.0 million.
Who are the underwriters for Metsera's IPO?
The joint bookrunners for Metsera's IPO include BofA Securities, Goldman Sachs, Evercore ISI, Guggenheim Securities, and Cantor Fitzgerald.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions, today announced the pricing of its initial public offering of 15,277,778 shares of its common stock at a price to the public of $18.00 per share. All of the shares of common stock are being offered by Metsera. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Metsera, are expected to be approximately $275.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. Metsera’s common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “MTSR” on January 31, 2025. The offering is expected to close on February 3, 2025, subject to satisfaction of customary closing conditions. In addition, Metsera has granted the underwriters a 30-day option to purchase up to an additional 2,291,666 shares of common stock at the initial public offering price less underwriting discounts and commissions.
BofA Securities, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities and Cantor are acting as joint bookrunners for the offering.
A registration statement on Form S-1 (File No. 333-284225) relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at Prospectus-ny@ny.email.gs.com; Evercore Group L.L.C., 55 East 52nd Street, 35th Floor, New York, NY 10055, Attn: Equity Capital Markets, or by email at ecm.prospectus@evercore.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Contact
Vicki Albrecht
Metsera
media@metsera.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
